Navigation Links
Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
Date:1/10/2008

INCHEON, South Korea, Jan. 10 /PRNewswire/ -- Celltrion, Inc., a Korean biopharmaceutical company whose core business is currently contract manufacturing, and CSL Limited, Australia's leading biopharmaceutical company, announced today the signing of an agreement for the development and supply of CSL 360, an experimental monoclonal antibody therapy for the treatment of acute myeloid leukemia (AML). Phase I clinical trials for CSL 360 are currently being conducted by CSL in Australia.

As part of the collaboration, Celltrion will provide process development expertise and supply clinical and commercial material to support the clinical development program for CSL 360 and commercialization of the product, with the potential for a longer term strategic manufacturing relationship between the companies in the future.

"Celltrion and its employees are completely committed to world-class quality in biopharmaceutical manufacturing, to assisting CSL in achieving the successful completion of clinical trials, and to providing manufacturing support for CSL's product commercialization," said Jung-Jin Seo, Celltrion's Chairman and Chief Executive Officer.

"Superior quality biopharmaceutical manufacturing facilities of this type are a scarce commodity in this region and we are delighted to have signed this collaboration to provide CSL with the opportunity to facilitate the clinical development of CSL 360 and potentially other exciting future recombinant protein opportunities," said Dr. Brian McNamee, CSL's Chief Executive Officer.

About Celltrion

Celltrion, established in 2002, is a contract manufacturing organization with a headquarters in Incheon, South Korea. Celltrion, an emerging leader in the biopharmaceutical industry, is dedicated to providing high quality services to accelerate product development, while offering scalable manufacturing capabilities for our clients and business partners. Celltrion is also investing in research and development of its own products, as well as licensing from biopharmaceutical research companies throughout the world, in order to develop into a fully integrated biotechnology company. For more information, please visit Celltrion's website at http://www.celltrion.com.

About CSL Limited

Headquartered in Melbourne, Australia, CSL Limited (ASX: CSL) is a global, specialty biopharmaceutical company that develops, manufactures and markets protein-based medicines to treat and prevent serious human medical conditions. The CSL Group has a combined heritage of outstanding contributions to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies. Our strong commitment to funding research and development of protein based biological medicines for unmet medical needs underpins our continuing growth.

The CSL Group includes CSL Bioplasma, CSL Biotherapies and CSL Behring incorporating ZLB Plasma. With major facilities in Australia, Germany, Switzerland and the U.S., CSL has over 8,600 employees operating in 27 countries.

For additional information, please contact:

Seung-Suh Hong, Ph.D.

Senior Vice President - Business Development

Celltrion, Inc. (U.S.A.)

Email: seungsuh.hong@celltrion.com

Tel: + 1 650 766 2307


'/>"/>
SOURCE Celltrion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that ... New Product Innovation Award for Its fibromyalgia pain management ... medical device market research by Frost & Sullivan,s industry experts. ... pain relief product, the AVACEN 100, offers a safe and ... pain. ...
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take certain medications ... from Austin, Texas, has identified a solution. , She developed a prototype for MOTION ... As such, it eliminates the need to turn on a light when taking medication ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of ... part of a disaster drill on October 3rd. , Apple Rehab participated with the ... as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
Breaking Medicine News(10 mins):